Quantcast

Latest TroVax Stories

2010-04-15 11:41:00

COLUMBIA, Md., April 15 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN) today announced that Dr. Ronnie T.P. Poon, a principal investigator of the Phase I ThermoDox® dose escalation trial, held a press conference at the University of Hong Kong to provide an update on the long-term follow-up data from patients treated at his center as well as present illustrative patient case studies. The Phase I trial was conducted in 2006. A presentation of the press...

2010-04-12 06:30:00

COLUMBIA, Md., April 12 /PRNewswire/ -- Celsion Corporation (Nasdaq: CLSN) today announced that Dr. Ronnie T.P. Poon from the University of Hong Kong and lead principal investigator for the Asia Pacific region of the Phase I ThermoDox® dose escalation trial will hold a press conference on Thursday, April 15, 2010 at 10:30 AM HKT (Wednesday, April 14, 2010 10:30 PM ET) to discuss the long-term follow-up of patients treated from April 2006 to December 2006. The majority of...

2010-04-09 09:49:17

Leukemia related protein 16 (LRP16) gene is an important estrogen-responsive gene. LRP16 gene plays an important role in the carcinogenesis and progression of hormone-dependent cancer. LRP16 expression was also reported to be associated with invasion, metastasis and prognosis of gastric carcinoma. But no comprehensive description of LRP16 protein expression in colorectal cancer has been reported. A research article published on April 7, 2010 in the World Journal of Gastroenterology addresses...

2010-03-09 06:30:00

CALGARY, March 9 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the year ended December 31, 2009. "In 2009, we executed on our business plan focused on preparing the Company for late stage clinical testing and ultimately commercial launch by making substantial clinical progress, strengthening our intellectual property position and balance sheet, and scaling up...

2010-03-03 17:07:00

BRIDGEWATER, N.J., March 3 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today results from a Phase 3 trial which demonstrated cabazitaxel, an investigational compound, plus prednisone/prednisolone significantly improved overall survival and progression-free survival in patients with metastatic (advanced) hormone-refractory prostate cancer whose disease progressed following treatment with docetaxel-based chemotherapy. The TROPIC trial compared the...

2010-02-25 12:02:00

BELLEVUE, Wash., Feb. 25 /PRNewswire/ -- Light Sciences Oncology, Inc. (LSO) today announced the achievement of a major milestone in its late-stage clinical development of Aptocine(TM) (talaporfin sodium) for treatment of solid tumors. LSO's global Phase 3 trial of Aptocine in metastatic colorectal cancer (MCRC) has reached target enrollment of 450 patients at 52 sites. The controlled, randomized MCRC trial is being conducted to assess the progression free survival (PFS) and overall...

2010-02-11 12:55:00

AMES, Iowa, Feb. 11 /PRNewswire/ -- NewLink Genetics Corporation announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for a pivotal Phase 3 trial of its HyperAcute immunotherapy in pancreatic cancer. Pancreatic cancer is highly lethal and is currently an area of very significant unmet medical need. The SPA is a written agreement between NewLink as the trial sponsor and the FDA regarding the design,...

2010-02-04 15:24:37

The drug pazopanib (Votrient) slowed the progression of advanced renal cell carcinoma (RCC), a form of kidney cancer, in patients by 54% percent, according to a new study published in the Journal of Clinical Oncology. "Advanced renal cell carcinoma remains a challenging disease, but the outlook for patients has improved in the past year "“ including the addition of pazopanib, which targets multiple pathways within cancer cells," study author Dr. Cora N. Sternberg, chief of the medical...

2010-02-03 07:30:00

NEW YORK, Feb. 3 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for its PI3K/Akt pathway inhibitor, KRX-0401 (perifosine), in patients with refractory metastatic colorectal cancer. The SPA provides agreement that the Phase 3 study design adequately addresses objectives in support of a...

2010-01-25 06:30:00

COLUMBIA, Md., Jan. 25 /PRNewswire-FirstCall/ -- CELSION CORPORATION (Nasdaq: CLSN) announced today that it will host a Research and Development Day for the financial community on Wednesday, February 24, 2010 from 7:30 AM - 10:30 AM ET in New York City. The event will be webcast live and archived for 90 days on the Company's website at http://www.celsion.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related